Takeaways NEW
- This development strengthens the market position of Bristol Myers Squibb and could positively influence investors.
- FDA approves a new, more convenient injection form of the cancer drug Opdivo.
A significant decision by the U.S. regulatory authority FDA brings relief to patients and the pharmaceutical company Bristol Myers Squibb. The authority has granted approval for an injectable form of the well-known cancer drug Opdivo. This development falls into the class of so-called PD-1 inhibitors, which support the immune system in fighting cancer by removing the body's own inhibitory mechanisms. Until now, Opdivo, similar to the drug Keytruda by Merck, was only available as an intravenous infusion in medical facilities. With the new injection option, patients now receive a more convenient application variant, which also potentially secures the company's revenues when the patent for the current infusion form expires towards the end of the decade. The current approval strengthens Bristol Myers Squibb's position in a highly competitive market and underscores the company's strategic efforts to continue demonstrating leadership in innovation. This development not only benefits patients but could also positively influence investor sentiment.
Eulerpool Markets
Finance Markets
New ReleaseEnterprise Grade
Institutional
Financial Data
Access comprehensive financial data with unmatched coverage and precision. Trusted by the world's leading financial institutions.
- 10M+ securities worldwide
- 100K+ daily updates
- 50-year historical data
- Comprehensive ESG metrics

Save up to 68%
vs. legacy vendors